Drug Development in Neuroendocrine Tumors: What Is on the Horizon?

A. Garcia-Alvarez; Jorge Hernando Cubero; Jaume Capdevila

doi:https://doi.org/10.1007/s11864-021-00834-3

doi.org/10.1007/s11864-021-00834-3

Drug Development in Neuroendocrine Tumors: What Is on the Horizon?

A. Garcia-Alvarez

4

,

Jorge Hernando Cubero

1

,

Jaume Capdevila

39

Current Treatment Options in Oncology4.30

Volume: 22, Issue: 5

Published: Mar 30, 2021

Abstract

Neuroendocrine neoplasms (NENs) constitute a heterogenous group of malignancies. Translational research into NEN cell biology is the cornerstone for drug development strategies in this field. Somatostatin receptor type 2 (SSTR2) expression is the hallmark of well-differentiated neuroendocrine tumors (NETs). Somatostatin analogs and peptide receptor radionuclide therapy (PRRT) form the basis of anti-SSTR2 treatment onto new combination...